Connect Biopharma Holdings Ltd (CNTB) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-07-01

Connect Biopharma Holdings Ltd (CNTB) has filed 3 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-01. 2 Form 8-K material event filings were reported by CNTB in the last 90 days. InsiderAlpha tracks every CNTB SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Connect Biopharma Holdings Ltd (CNTB)

SEC CIK	0001835268

90-Day SEC Filing Activity

Form 4 filings (90d)	3
Form 8-K filings (90d)	2
Latest Form 4 filing	2026-07-01

Recent CNTB Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-06-30	Xanthopoulos Kleanthis Gabriel	Director	A — Grant or award	3.7K	$0.00	—	SEC
2026-06-30	LIU JEAN I	Director	A — Grant or award	6.7K	$0.00	—	SEC
2026-05-29	Huang James	Insider	P — Open-market purchase	150.0K	$2.48	$372K	SEC
2026-03-31	Huang James	Insider	P — Open-market purchase	1.16M	$3.45	$4.00M	SEC
2026-03-31	Xanthopoulos Kleanthis Gabriel	Director	A — Grant or award	2.8K	$0.00	—	SEC
2026-03-31	LIU JEAN I	Director	A — Grant or award	5.1K	$0.00	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Connect Biopharma Holdings Ltd (CNTB). Updated in real time as new filings are submitted to the SEC.

Most-Active CNTB Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
LIU JEAN I	1	—
Huang James	1	$372K
Xanthopoulos Kleanthis Gabriel	1	—

Recent CNTB Form 8-K Material Events

2026-05-12 — Item 2.02, 9.01 [SEC]
2026-04-23 — Item 7.01, 8.01, 9.01 · Clinical · positive [SEC]
Connect Biopharma announced that the independent Data Monitoring Committee (DMC) completed its review of the pre-specified interim analysis of efficacy for its Phase 2 Seabreeze STAT trials evaluating rademikibart (anti-IL-4Rα antibody) in asthma and COPD, with no recommendation

Recent Insider Filings

2026-07-01 — Xanthopoulos Kleanthis Gabriel (Director)
2026-07-01 — LIU JEAN I (Director)
2026-06-02 — Huang James (Insider)
2026-04-02 — Xanthopoulos Kleanthis Gabriel (Director)
2026-04-02 — LIU JEAN I (Director)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in CNTB insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

CNTB Insider Trading — FAQ

What is the latest insider trade for CNTB?: Connect Biopharma Holdings Ltd (CNTB) had 3 insider filings in the last 90 days, with the most recent on 2026-07-01. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying CNTB stock?: 0 insider purchases of CNTB were filed in the last 90 days.
How many insiders are selling CNTB stock?: 0 insider sales of CNTB were filed in the last 90 days.
Where can I see CNTB SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every CNTB SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live CNTB dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.